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any evidence-based conditions. Risperidone had the lowest levels
of non-evidence base use of (30.59%) and aripiprazole had the
highest (77.13%). CONCLUSION: The rate of atypical antipsy-
chotic use in pediatrics has doubled between 2001 and 2005 and
a large proportion of the usage in the Arkansas Medicaid pedi-
atric population is not based on strong clinical evidence.
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OBJECTIVE: Anticholinergic medications (ACH) have clinical
beneﬁts but also impair cognitive function in older adults and
may counteract beneﬁts of cholinesterase inhibitors (CHI) in
Alzheimer’s and other dementias. Prevalence of ACH use and
concomitant ACH and CHI use among Indiana Medicaid
recipients in nursing homes with dementia was determined.
METHODS: A retrospective cross-sectional analysis of Indiana
Medicaid claims and enrollment ﬁles identiﬁed persons 65 y/o or
older with dementia who took CHI anytime in 2004 and were
Medicaid-eligible and in nursing homes continuously in 2004.
Dementia was identiﬁed using 26 ICD-9 diagnosis codes deter-
mined in a prior study as speciﬁc for dementia. To exclude
persons with just a trial of CHI, only persons receiving a second
CHI prescription within 30 days of the end of the indicated
days-supply of a prior CHI prescription were classiﬁed as CHI
users. Only users of drugs identiﬁed in published reports as
having clinically signiﬁcant ACH adverse effects (Level 2) or
markedly ACH adverse effects (Level 3) were classiﬁed as ACH
users. Concomitant use was deﬁned as overlap in periods covered
by CHI and ACH supply. Days of concomitant use and ACH
activity levels also were examined. RESULTS: The sample of
3251 individuals had a mean age of 83 years, was 75% female
and, 89% white. Among these, 1,888, 58.07%, (95%
CI = 56.38–59.77) received an ACH some time during the year
and 1519, 46.72% (95% CI = 45.01–48.44) received an ACH
concomitantly with CHI. Among concomitant users, mean
number of days of concomitant use was 158.96 days (95%
CI = 152.61–165.31) and a majority, 58.13% (95% CI = 55.65–
60.61) received a Level 3 ACH concomitantly with CHI. CON-
CLUSION: Concomitant ACH and CHI use was high among
nursing home residents with dementia. Assessing opportunities
for alternatives might lead to strategies for tackling this thera-
peutic dilemma.
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OBJECTIVE: This study was designed to determine the degree to
which second-generation antipsychotics were used off-label for
patients with bipolar disorder (BPD) and to identify patient
characteristics which were most associated with off-label second-
generation antipsychotic use. METHODS: The multi-state
(PHARMetrics) medical claims database was used to evaluate
105,771 adult patients with a diagnosis of bipolar disorder. The
study period was between 1998–2002. The off-label use of a
second-generation antipsychotic medication was deﬁned as a
patient either receiving olanzapine before March 2000 or any
second-generation antipsychotic, other than olanzapine, during
the entire study period. Olanzapine was differentiated from the
others in its class because it was approved for use in BPD in
2000. Multivariate logistic regression analysis was used to assess
the risk of receiving a drug off-label. RESULTS: Sixty-three
percent of the patients were female, and the mean age was 40.3
years. Eleven percent of patients were on lithium, 25% received
other anticonvulsants, 34% were treated with antidepressants,
and 10.5% (7.1% off-label) took second-generation antipsychot-
ics. A higher risk of off-label use was associated with psychiatry
specialist prescribers (Odds Ratio = 1.52, 95% Conﬁdence Inter-
val 1.44–1.59) and certain comorbidities such as substance
abuse (OR = 1.51, 1.38–1.66), anxiety disorder (OR = 1.20,
1.14–1.26), diabetes mellitus (OR = 1.26, 1.16–1.37), cerebral
vascular disease (OR = 1.26, 1.10–1.45), and hypertension
(OR = 1.12, 1.05–1.20). CONCLUSION: The off-label use of
second-generation antipsychotics in treating BPD was fairly
common from 1998–2002 and their use was associated with
some key clinical factors. Our results add to a growing literature
that relationship links the use of newer antipsychotics with dia-
betes, hypertension, obesity, and cerebral-vascular disease.
PMH73
INITIATION OF ATOMOXETINEVS. STIMULANTS FOR
CHILDRENWITH ADHD IN MEDICAID SETTINGS
Van Brunt D1,Ye W1, Pohl G1,Von Allmen H2
1Eli Lilly and Company, Indianapolis, IN, USA, 2IMS Health, Blue Bell,
PA, USA
OBJECTIVE: To identify factors associated with treatment ini-
tiation of atomoxetine (ATX), stimulants (STIM), or long-acting
stimulants (LA-STIM) in children with ADHD using Medicaid.
METHODS: Data were from the IMS Health LRx Database.
Patients covered by Medicaid age <18 years old were selected if
they initiated treatment with an ADHD medication categorized
as ATX, any STIM, or LA-STIM between January 2005 and
December 2005. Initiation was deﬁned as the ﬁrst use of a
medication preceded by 120 days without a prescription in the
same category. Stepwise logistic regression was used to identify
the factors associated with initiations of ATX vs. STIM or ATX
vs. LA-STIM adjusting for age (0–5 vs. 6–12, 13–17 vs. 6–12),
gender, prior ADHD medications, other concomitant psychiatric
medications, provider specialty, and a number of unique of pre-
vious ADHD medications used. RESULTS: A total of 24,141
patients (68.62% male) most recently initiated treatment with
ATX, 144,451(68.84% male) with STIM, and 129,323 (68.82%
male) with LA-STIM. Increasing age was associated with
increased likelihood of ATX initiation (p < .05) relative to
STIM. Other signiﬁcant factors (all p-value < 0.001) were initia-
tion concomitant with use of antidepressants (OR = 1.29),
antimanics (OR = 1.34), antipsychotics (OR = 1.49), anxiolytics
(OR = 1.69), or anticonvulsants (OR = 1.33). ATX initiation
also became more likely with increasing number of historical
ADHD treatment episodes. Pediatricians were more likely to
prescribe STIM over ATX relative to general psychiatrists
(OR = 0.76). Factors for initiation of ATX vs. LA-STIM were
similar to those for the STIM comparisons. CONCLUSION: The
factors associated with initiation of ATX vs. STIM or ATX vs.
LA-STIM suggest that despite common indications, atomoxetine
and stimulants may be addressing different needs. The ﬁndings
suggest that ATX is preferentially prescribed for patients with
psychiatric comorbidities or potentially complicated treatment
proﬁles.
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